Atsushi Kimbara

Novel Triazolopyrimidine‐Derived Cannabinoid Receptor 2 Agonists as Potential Treatment for Inflammatory Kidney Diseases

W. Guba, T. Schulz-Gasch, Benno Rothenhäusler, 2016, ChemMedChem.

Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis

W. Guba, Benno Rothenhäusler, U. Grether, 2019, Molecules.

Highly potent and selective cannabinoid receptor 2 agonists: initial hit optimization of an adamantyl hit series identified from high-through-put screening.

T. Schulz-Gasch, F. Schuler, U. Grether, 2013, Bioorganic & medicinal chemistry letters.

Total synthesis and stereochemistry revision of mannopeptimycin aglycone.

K. Shin‐ya, T. Doi, M. Izumikawa, 2014, Journal of the American Chemical Society.

NF‐κB activation in astrocytes drives a stage‐specific beneficial neuroimmunological response in ALS

T. Boeckers, C. Rapôso, A. Ludolph, 2018, The EMBO journal.

Diverse chemotypes drive biased signaling by cannabinoid receptors

W. Guba, A. Rufer, D. Veprintsev, 2020, bioRxiv.

RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models

C. Bissantz, F. Fezza, U. Grether, 2024, Frontiers in pharmacology.